Novelix Pharmaceuticals Ltd - 536565 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Novelix Pharmaceuticals promoters Srinidhi Fine-Chemicals LLP and Narahari Belide acquired 1.15 million shares. This acquisition on March 30, 2026, was through conversion of warrants via a preferential allotment, increasing their combined stake in the company.
Apr 02 2026 10:04:00
Novelix Pharmaceuticals Ltd - 536565 - Announcement under Regulation 30 (LODR)-Allotment
Novelix Pharmaceuticals allotted 11.5 lakh equity shares from warrant conversion at ₹20 each. This capital raise generated ₹2.3 crore and increased the company's paid-up equity capital to ₹2.10 crore.
Mar 31 2026 15:03:00
Novelix Pharmaceuticals Ltd - 536565 - Intimation Under Regulation 30 (LODR), Regulations 2015- Reconstitution Of Committees.
Novelix Pharmaceuticals board reconstituted its Audit, Nomination & Remuneration, and Stakeholders Relationship Committees. Janardhan Das Kabra will chair the Audit and N&R Committees, while Sridevi Belide will lead the Stakeholders Relationship Committee, effective March 30, 2026.
Mar 31 2026 15:03:00
Novelix Pharmaceuticals Ltd - 536565 - Board Meeting Outcome for Outcome Of Board Meeting Held On 30Th April, 2026
Novelix Pharmaceuticals board approved the allotment of 11.5 lakh equity shares at ₹20 each upon warrant conversion. This increased the paid-up equity capital to ₹2.1085 crore. Additionally, the board accepted the resignation of Non-Executive Director Jivamohan Divakar Valluri, effective March 30, 2026.
Mar 30 2026 19:03:00
Read More